Amicus Therapeutics Inc (NASDAQ: FOLD) is -40.83% lower on its value in year-to-date trading and has touched a low of $5.51 and a high of $12.65 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FOLD stock was last observed hovering at around $6.07 in the last trading session, with the day’s gains setting it 0.22%.
Currently trading at $6.29, the stock is 5.47% and 3.61% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 5.22 million and changing 3.62% at the moment leaves the stock -26.67% off its SMA200. FOLD registered -33.23% loss for a year compared to 6-month loss of -31.70%. The firm has a 50-day simple moving average (SMA 50) of $6.1028 and a 200-day simple moving average (SMA200) of $8.6501.
The stock witnessed a 3.97% gain in the last 1 month and extending the period to 3 months gives it a -8.84%, and is -0.16% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.90% over the week and 3.90% over the month.
Amicus Therapeutics Inc (FOLD) has around 499 employees, a market worth around $1.94B and $543.14M in sales. Fwd P/E is 24.35. Profit margin for the company is -5.41%. Distance from 52-week low is 14.16% and -50.28% from its 52-week high. The company has generated returns on investments over the last 12 months (-4.67%).
The EPS is expected to grow by 51.94% this year
378.0 institutions hold shares in Amicus Therapeutics Inc (FOLD), with institutional investors hold 103.55% of the company’s shares. The shares outstanding are 307.92M, and float is at 297.12M with Short Float at 7.16%. Institutions hold 102.81% of the Float.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 28.59 million shares valued at $283.6 million. The investor’s holdings represent 9.4111 of the FOLD Shares outstanding. As of 2024-06-30, the second largest holder is PERCEPTIVE ADVISORS LLC with 28.06 million shares valued at $278.33 million to account for 9.2363 of the shares outstanding. The other top investors are AVORO CAPITAL ADVISORS LLC which holds 27.4 million shares representing 9.0199 and valued at over $271.81 million, while BLACKROCK INC. holds 8.023 of the shares totaling 24.37 million with a market value of $241.77 million.
Amicus Therapeutics Inc (FOLD) Insider Activity
The most recent transaction is an insider sale by Campbell Bradley L, the company’s President and CEO. SEC filings show that Campbell Bradley L sold 400 shares of the company’s common stock on Feb 19 ’25 at a price of $10.00 per share for a total of $4000.0. Following the sale, the insider now owns 1.15 million shares.
Still, SEC filings show that on Dec 02 ’24, Campbell Bradley L (President and CEO) disposed off 7,500 shares at an average price of $10.02 for $75124.0. The insider now directly holds 886,654 shares of Amicus Therapeutics Inc (FOLD).
